This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN
by Zacks Equity Research
The Medical sector is expected to stand out on favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, and a value-based payment system.
Intuitive Surgical Gains on FDA Approvals, Competition Rife
by Zacks Equity Research
Intuitive Surgical (ISRG) gains significantly on CE Mark approval for da Vinci X in Europe.
Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from revenue growth in Instrument & Accessories plus Services and Systems segments in Q4.
Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance
by Zacks Equity Research
Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.
Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q2.
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.
Walgreens Boots' Retail Pharmacy Strong, Competition Rife
by Zacks Equity Research
Walgreens Boots (WBA) rides high on continued prescription growth and strength in the Retail Pharmacy USA division.
PetMed (PETS) Q3 Earnings Top Estimates, Reorder Sales Solid
by Zacks Equity Research
The upside in third-quarter fiscal 2018 sales at PetMed (PETS) is a result of the significant increase in new orders and reorder sales.
ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.
Abiomed Hits New 52-Week High: 3 Factors Driving the Stock
by Zacks Equity Research
Abiomed (ABMD) recently reported strong preliminary third-quarter fiscal 2018 results.
Zacks.com highlights: Caterpillar, Crocs, Pioneer Natural Resources, Legg Mason and Intuitive Surgical
by Zacks Equity Research
Zacks.com highlights: Caterpillar, Crocs, Pioneer Natural Resources, Legg Mason and Intuitive Surgical
Becton, Dickinson Completes Enrollment in Lutonix DCB Trial
by Zacks Equity Research
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.
Medtronic's FDA Nod for Riptide Aspiration System Boosts RTG
by Zacks Equity Research
Medtronic (MDT) makes efforts to boost RTG business.
Becton, Dickinson Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) rides on favorable regulatory developments and strategic acquisitions.
5 Top Stocks Powered by Beat Potential This Earnings Season
by Zacks Equity Research
Bet on five stocks that are likely to outdo earnings estimates.
Medtronic (MDT) Wins FDA Nod for New Clinician Programmer
by Zacks Equity Research
Medtronic's (MDT) latest FDA nod likely to boost Pain Therapies division.
5 Reasons Why You Should Offload Wright Medical Stock Now
by Zacks Equity Research
Foreign currency fluctuations and pricing pressure continue to be major headwinds for Wright Medical Group (WMGI).
5 Reasons Why McKesson Deserves a Place in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.
Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) is expected to witness growth across da Vinci Surgical and Service segments. Instruments and accessories revenues are also expected to increase year over year.
Medtronic's ITB Therapy Superior to CMM for PSS Reduction
by Zacks Equity Research
Medtronic (MDT) consistently tries efforts to boost Pain Therapies division, part of the Restorative Therapies Group.
Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.
QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.
Express Scripts 90-Day Analysis of Opioid Management Positive
by Zacks Equity Research
Express Scripts (ESRX) addresses the national opioid epidemic by reducing excessive and improper opioid use.
Henry Schein (HSIC) Buys ABASE, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.
Baxter (BAX) Launches Arisure Closed System Transfer Device
by Zacks Equity Research
Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.